Projects per year
Abstract
Acute myeloid leukemia (AML) is a very heterogeneous type of blood cancer, which presents with a high rate of mortality especially in elderly patients. Better understanding of critical players, such as molecules with tumor suppressive properties, may help to fine-tune disease classification and thereby treatment modalities for this detrimental disease. Here, we summarize well-known and established tumor suppressors as well as emerging tumor suppressors, including transcription factors (TCFs) and other transcriptional regulators, such as epigenetic modulators. In addition, we look into the versatile field of miRNAs also interfering with tumorigenesis and progression, which offer new possibilities in AML diagnosis, prognosis, and therapy.
| Original language | English |
|---|---|
| Pages (from-to) | 2320-2330 |
| Number of pages | 11 |
| Journal | Leukemia and Lymphoma |
| Volume | 62 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - Oct 2021 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Aged
- Carcinogenesis
- Cell Transformation, Neoplastic
- Humans
- Leukemia, Myeloid, Acute/diagnosis
- MicroRNAs/genetics
- Prognosis
- transcription factor
- epigenetic regulator
- miRNA
- tumor suppressor
- Acute myeloid leukemia
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
Fingerprint
Dive into the research topics of 'Tumor suppressors in acute myeloid leukemia'. Together they form a unique fingerprint.Projects
- 1 Finished
-
STAT3 isoforms : STAT3 isoforms in acute myeloid leukemia
01.02.2020 → 31.07.2025
Project: Funded Research
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver